Wellington Management Group LLP Sells 11,951 Shares of Harrow, Inc. (NASDAQ:HROW)

Wellington Management Group LLP cut its stake in Harrow, Inc. (NASDAQ:HROW - Free Report) by 11.6% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 91,228 shares of the company's stock after selling 11,951 shares during the period. Wellington Management Group LLP owned 0.26% of Harrow worth $3,061,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the company. AlphaQuest LLC lifted its stake in shares of Harrow by 452.8% in the 4th quarter. AlphaQuest LLC now owns 3,527 shares of the company's stock valued at $118,000 after purchasing an additional 2,889 shares during the period. Virtu Financial LLC purchased a new stake in shares of Harrow in the 3rd quarter worth about $271,000. Maridea Wealth Management LLC purchased a new stake in shares of Harrow in the 4th quarter worth about $222,000. KLP Kapitalforvaltning AS bought a new position in shares of Harrow in the 4th quarter worth about $235,000. Finally, Principal Financial Group Inc. purchased a new position in Harrow during the 3rd quarter valued at about $329,000. 72.76% of the stock is owned by institutional investors.

Harrow Stock Up 0.9 %

Harrow stock traded up $0.22 during trading hours on Thursday, hitting $23.57. The stock had a trading volume of 49,274 shares, compared to its average volume of 506,674. The stock's 50-day moving average price is $26.44 and its 200-day moving average price is $35.99. The stock has a market capitalization of $840.19 million, a P/E ratio of -25.13 and a beta of 0.46. Harrow, Inc. has a 12-month low of $9.86 and a 12-month high of $59.23. The company has a quick ratio of 1.44, a current ratio of 1.55 and a debt-to-equity ratio of 3.23.

Harrow (NASDAQ:HROW - Get Free Report) last released its quarterly earnings data on Thursday, March 27th. The company reported $0.25 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.11 by $0.14. Harrow had a negative return on equity of 45.57% and a negative net margin of 19.75%. The business had revenue of $66.83 million for the quarter, compared to analysts' expectations of $66.01 million. Equities research analysts anticipate that Harrow, Inc. will post -0.53 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on HROW shares. B. Riley decreased their target price on shares of Harrow from $69.00 to $65.00 and set a "buy" rating for the company in a research note on Tuesday, April 1st. HC Wainwright reaffirmed a "buy" rating and set a $57.00 price objective on shares of Harrow in a research report on Monday, March 31st.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.